Note: The material presented in this commentary is provided for informational purposes only and is based upon information that is considered to be reliable. However, neither PSW Investments, LLC d/b/a PhilStockWorld (PSW) nor its affiliates warrant its completeness, accuracy or adequacy and it should not be relied upon as such. Neither PSW nor its affiliates are responsible for any errors or omissions or for results obtained from the use of this information. Past performance, including the tracking of virtual trades and portfolios for educational purposes, is not necessarily indicative of future results. Neither Phil, Optrader, or anyone related to PSW is a registered financial adviser and they may hold positions in the stocks mentioned, which may change at any time without notice. Do not buy or sell based on anything that is written here, the risk of loss in trading is great.
This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities or other financial instruments mentioned in this material are not suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only intended at the moment of their issue as conditions quickly change. The information contained herein does not constitute advice on the tax consequences of making any particular investment decision. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation to you of any particular securities, financial instruments or strategies. Before investing, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.
Contact us: support@philstockworld.com
© Copyright - PSW, LLC.
2024
December 13th, 2017 at 11:21 am
TEVA
12-Dec-17 07:22 ET
TEVA
Teva Pharma shares slip 2% in early trade amid reports it may look to refinance its debt early next year (16.44)
11-Dec-17 12:19 ET
MYL
Mylan N.V. announces that Teva (TEVA) has dismissed its pending district court litigation against Mylan regarding Mylan's Glatiramer Acetate Injection 40 mg/mL, the first generic version of Copaxone 40 mg/mL (39.13 +0.46)
The litigation involved two non-Orange Book listed patents, U.S. Patent Nos. 9,155,775 and 9,763,993, relating to the final sterile filtration step in the manufacturing process for glatiramer acetate products.
Teva dropped litigation on these patents after the U.S. District Court for the District of Delaware issued a decision adopting Mylan's interpretation of the patents' claims.
In addition, Teva has agreed to withdraw the Irish equivalent to these patents from the recently filed proceeding in Ireland.
After the dismissals, Teva's only remaining patent challenges in the U.S. and Ireland against Mylan's Glatiramer Acetate Injection 40mg/mL relate to the three-times-a-week dosing regimen, which Mylan has already successfully invalidated at the U.S. District Court for Delaware, the U.S. Patent Trial and Appeal Board and the United Kingdom's High Court of Justice. Teva is appealing these decisions.
11-Dec-17 10:49 ET
IBB
FDA head Scott Gottlieb favors generic drugs to combat high drug prices, according to FT (106.11)
FT Article (Note: In early October, FDA confirmed it is pursuing ways to streamline the generics drug review process. Related Stocks: PRGO, TEVA, MYL, VRX, IPXL, MNK, ENDP, LCI, AKRX).
11-Dec-17 09:15 ET
TEVA
Teva Pharma announces launch of generic Viagra tablets in the United States (16.06)
08-Dec-17 10:52 ET
TEVA
Teva Pharma considering eliminating 10K jobs, according to Bloomberg (15.65 +0.64)
Bloomberg Article